Skip to main content

Table 2 Duration of meropenem and concomitant antimicrobial therapy

From: Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial

 

Standard-dose meropenem (n = 38)

High-dose meropenem (n = 38)

P value

Day of meropenem therapy, median (IQR)

6 (3–16)

5 (3–21)

0.035*

Concomitant antimicrobial therapy, n (%)

16 (42.1)

19 (50)

0.646

 Colistin, n (%)

3 (18.8)

2 (10.5)

0.642

 Vancomycin, n (%)

7 (43.8)

6 (31.6)

0.503

 Cotrimoxazole, n (%)

1 (6.3)

4 (21.1)

0.347

 Levofloxacin, n (%)

0 (0)

3 (15.8)

0.234

 Amikacin, n (%)

4 (25)

3 (15.8)

0.677

 Azithromycin, n (%)

1 (6.3)

2 (10.5)

1.000

 Oseltamivir, n (%)

2 (12.5)

2 (10.5)

1.000

De-escalation, n (%)

21 (55.3)

25 (65.8)

0.436

  1. *Statistically significant difference